| Name | Title | Contact Details |
|---|
Elementis Specialties (RHEOX) is a Hightstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Center of McKinney (MCM) is a growing 260-bed hospital with a 90-year history of serving the health care needs of McKinney and the surrounding communities. Over the past several years, MCM has strengthened its medical foundations by adding two new surgical robots, a newly remodeled labor and delivery suites, a Level III Neonatal Intensive Care Unit (NICU) and an advanced biplane Catheterization (cath) lab to treat heart rhythm disorders. Medical Center of McKinney will be expanding its services to the community with the addition of a new off-campus emergency department at 380 & Custer in 2015.
It`s good to be home! Jet Health is a provider of skilled home health, hospice, personal care, and companion services. Founded in April 2016, Jet Health is building a national platform through organic growth, strategic acquisitions, and de novo build-outs in target markets. These markets are typically mid-sized cities that have under served and growing Medicare populations. Jet Health leverages local brands and operating expertise while sharing best practices across its companies and centralizes traditional back office functions. The company believes that its four cornerstones: superior service, clinical excellence, compliant business practices and an employee centric environment, provide a solid foundation upon which to build a successful company in the home health marketplace.
Fresenius SE & Co. KGaA is a health care company based in Bad Homburg vor der Höhe, Germany.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.